Identification of MAD2L1 as a Potential Biomarker in Hepatocellular Carcinoma via Comprehensive Bioinformatics Analysis

Table 1

Correlations between MAD2L1 expression and the clinicopathological features of hepatocellular carcinoma patients.

Characteristics		MAD2L1 expression		value
		Low	High
Age (years)
>50	50	20 (40.00%)	30 (60.00%)	0.343
≤50	40	20 (50.00%)	20 (50.00%)
Gender
Male	80	34 (42.50%)	46 (57.5%)	0.476
Female	10	6 (60.00%)	4 (40.00%)
AJCC stage
I	63	31 (49.21%)	32 (50.79%)	0.165
II-III	27	9 (33.33%)	18 (66.67%)
HBsAg
Negative	19	10 (52.63%)	9 (47.37%)	0.419
Positive	71	30 (42.25%)	41 (57.75%)
AFP (μg/L)
>400	33	15 (45.45%)	18 (54.54%)	0.883
≤400	57	25 (43.86%)	32 (56.14%)
Total bilirubin (μmol/L)
>20	15	7 (46.67%)	8 (53.33%)	0.850
≤20	75	33 (44.00%)	42 (56.00%)
ALT (U/L)
>45	32	15 (46.88%)	17 (53.12%)	0.730
≤45	58	25 (43.30%)	33 (56.70%)
GGT (U/L)
>40	59	24 (40.68%)	35 (59.32%)	0.321
≤40	31	16 (51.61%)	15 (48.39%)
Edmondson-Steiner grade
I & II	53	29 (54.72%)	24 (40.68%)	0.019
III & IV	37	11 (29.73%)	26 (70.27%)
Tumor number
1	79	35 (44.30%)	44 (55.70%)	0.943
>1	11	5 (45.45%)	6 (54.55%)
Tumor size (cm)
>5	28	8 (28.57%)	20 (71.43%)	0.042
≤5	62	32 (51.61%)	30 (48.39%)